ZA201006733B - Oxytocin analogues - Google Patents
Oxytocin analoguesInfo
- Publication number
- ZA201006733B ZA201006733B ZA2010/06733A ZA201006733A ZA201006733B ZA 201006733 B ZA201006733 B ZA 201006733B ZA 2010/06733 A ZA2010/06733 A ZA 2010/06733A ZA 201006733 A ZA201006733 A ZA 201006733A ZA 201006733 B ZA201006733 B ZA 201006733B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxytocin analogues
- oxytocin
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4097308P | 2008-03-31 | 2008-03-31 | |
| EP08251739 | 2008-05-19 | ||
| PCT/IB2009/005351 WO2009122285A1 (en) | 2008-03-31 | 2009-03-30 | Oxitocin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201006733B true ZA201006733B (en) | 2011-06-29 |
Family
ID=39722695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/06733A ZA201006733B (en) | 2008-03-31 | 2010-09-20 | Oxytocin analogues |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8673841B2 (https=) |
| EP (2) | EP2260053B1 (https=) |
| JP (1) | JP5539310B2 (https=) |
| KR (1) | KR101558404B1 (https=) |
| CN (1) | CN101983205B (https=) |
| AU (1) | AU2009233429B2 (https=) |
| BR (1) | BRPI0910345B1 (https=) |
| CA (1) | CA2718148C (https=) |
| DK (1) | DK2260053T3 (https=) |
| ES (1) | ES2488992T3 (https=) |
| HR (1) | HRP20140716T1 (https=) |
| IL (1) | IL208039A (https=) |
| MX (1) | MX2010010743A (https=) |
| NZ (1) | NZ587817A (https=) |
| PL (1) | PL2260053T3 (https=) |
| PT (1) | PT2260053E (https=) |
| RU (1) | RU2496788C2 (https=) |
| SI (1) | SI2260053T1 (https=) |
| WO (1) | WO2009122285A1 (https=) |
| ZA (1) | ZA201006733B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2575853B1 (en) | 2010-05-25 | 2016-08-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| EP2935312B1 (en) | 2012-12-21 | 2018-08-08 | F.Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| AU2015270723A1 (en) * | 2014-06-03 | 2016-11-17 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| ES2970059T3 (es) | 2014-09-19 | 2024-05-24 | Ferring Bv | Método de tratamiento del síndrome de Prader-Willi |
| CN106084015B (zh) * | 2016-08-25 | 2020-01-31 | 成都圣诺生物制药有限公司 | 一种合成卡贝缩宫素的方法 |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| BR112020001832A2 (pt) * | 2017-08-11 | 2020-07-28 | Ferring B.V. | método de produção de uma composição farmacêuti-ca |
| CN107628975B (zh) * | 2017-09-17 | 2019-10-29 | 贵州医科大学 | 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用 |
| EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
| TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 Ｃ 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
| JP7390031B2 (ja) * | 2018-12-27 | 2023-12-01 | 国立大学法人金沢大学 | オキシトシン誘導体及びその使用 |
| JP2023500763A (ja) * | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
| WO2022026463A1 (en) * | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Oxytocin analogues and methods for using the same |
| ES3010259T3 (en) | 2021-03-26 | 2025-04-01 | Ot4B | Treatment of dysphagia |
| WO2024044633A2 (en) * | 2022-08-23 | 2024-02-29 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Oxytocin derivatives and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| EP1480998B1 (en) * | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
-
2009
- 2009-03-30 EP EP09727031.8A patent/EP2260053B1/en active Active
- 2009-03-30 AU AU2009233429A patent/AU2009233429B2/en active Active
- 2009-03-30 PT PT97270318T patent/PT2260053E/pt unknown
- 2009-03-30 JP JP2011502454A patent/JP5539310B2/ja active Active
- 2009-03-30 SI SI200930966T patent/SI2260053T1/sl unknown
- 2009-03-30 DK DK09727031.8T patent/DK2260053T3/da active
- 2009-03-30 KR KR1020107024207A patent/KR101558404B1/ko active Active
- 2009-03-30 CN CN200980111919.5A patent/CN101983205B/zh active Active
- 2009-03-30 HR HRP20140716AT patent/HRP20140716T1/hr unknown
- 2009-03-30 ES ES09727031.8T patent/ES2488992T3/es active Active
- 2009-03-30 NZ NZ587817A patent/NZ587817A/en unknown
- 2009-03-30 US US12/933,858 patent/US8673841B2/en active Active
- 2009-03-30 MX MX2010010743A patent/MX2010010743A/es active IP Right Grant
- 2009-03-30 PL PL09727031T patent/PL2260053T3/pl unknown
- 2009-03-30 EP EP13156710.9A patent/EP2626364A1/en not_active Withdrawn
- 2009-03-30 WO PCT/IB2009/005351 patent/WO2009122285A1/en not_active Ceased
- 2009-03-30 RU RU2010139634/04A patent/RU2496788C2/ru active
- 2009-03-30 CA CA2718148A patent/CA2718148C/en active Active
- 2009-03-30 BR BRPI0910345-7A patent/BRPI0910345B1/pt active IP Right Grant
-
2010
- 2010-09-07 IL IL208039A patent/IL208039A/en active IP Right Grant
- 2010-09-20 ZA ZA2010/06733A patent/ZA201006733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2718148C (en) | 2017-11-07 |
| NZ587817A (en) | 2012-05-25 |
| ES2488992T3 (es) | 2014-09-01 |
| IL208039A0 (en) | 2010-12-30 |
| HK1146064A1 (en) | 2011-05-13 |
| MX2010010743A (es) | 2010-11-04 |
| US8673841B2 (en) | 2014-03-18 |
| BRPI0910345B1 (pt) | 2021-08-17 |
| US20110044905A1 (en) | 2011-02-24 |
| EP2260053A1 (en) | 2010-12-15 |
| CN101983205B (zh) | 2015-08-19 |
| SI2260053T1 (sl) | 2014-08-29 |
| KR101558404B1 (ko) | 2015-10-08 |
| BRPI0910345A2 (pt) | 2015-10-06 |
| CN101983205A (zh) | 2011-03-02 |
| DK2260053T3 (da) | 2014-06-23 |
| RU2010139634A (ru) | 2012-05-10 |
| AU2009233429B2 (en) | 2014-02-13 |
| WO2009122285A8 (en) | 2009-12-10 |
| HRP20140716T1 (hr) | 2014-08-29 |
| JP2011516460A (ja) | 2011-05-26 |
| EP2260053B1 (en) | 2014-05-14 |
| AU2009233429A1 (en) | 2009-10-08 |
| RU2496788C2 (ru) | 2013-10-27 |
| JP5539310B2 (ja) | 2014-07-02 |
| EP2626364A1 (en) | 2013-08-14 |
| IL208039A (en) | 2016-03-31 |
| PL2260053T3 (pl) | 2014-11-28 |
| KR20110005705A (ko) | 2011-01-18 |
| PT2260053E (pt) | 2014-08-29 |
| CA2718148A1 (en) | 2009-10-08 |
| WO2009122285A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208039A0 (en) | Oxytocin analogues | |
| IL213479A0 (en) | Glucagon analogues | |
| ZA201104593B (en) | Glucagon analogues | |
| IL213480A0 (en) | Glucagon analogues | |
| IL213477A0 (en) | Glucagon analogues | |
| EP2278675A4 (en) | SPOUT | |
| EP2276132A4 (en) | SPOUT | |
| EP2284970A4 (en) | SPOUT | |
| EP2276134A4 (en) | GROMMET | |
| EP2276133A4 (en) | SPOUT | |
| GB2479441B (en) | Coelenterazine analogues | |
| EP2248703A4 (en) | PASS CABLE | |
| GB2488742B (en) | Jigsaw | |
| TWI368572B (en) | Printing-table arrangement | |
| IL192579A0 (en) | Multi-bandage | |
| EP2285379A4 (en) | ANALOGUES OF 1-METHYLNICOTINAMIDE | |
| GB0820166D0 (en) | Former | |
| GB2463042B (en) | Stabalizer arrangement | |
| GB0821907D0 (en) | Scribe-it | |
| GB0805372D0 (en) | Pathfinder | |
| GB0805969D0 (en) | Clevertee pro | |
| GB0810438D0 (en) | Case | |
| GB0808765D0 (en) | Location | |
| AU323160S (en) | Canister | |
| AU323164S (en) | Canister |